Greg Harrison
Stock Analyst at B of A Securities
(4.63)
# 206
Out of 5,055 analysts
102
Total ratings
61.04%
Success rate
23.13%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Buy | $36 → $30 | $8.48 | +253.77% | 3 | Oct 27, 2025 | |
| UTHR United Therapeutics | Maintains: Neutral | $314 → $463 | $471.92 | -1.89% | 5 | Sep 2, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $38 → $43 | $44.26 | -2.85% | 2 | Aug 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $35.44 | -12.53% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $11.89 | +68.21% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $66.90 | -14.80% | 7 | Aug 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $442 → $438 | $434.02 | +0.92% | 7 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $460.54 | -2.29% | 6 | Aug 1, 2025 | |
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $71 → $65 | $45.13 | +44.03% | 7 | Jul 28, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $9 → $4 | $3.04 | +31.58% | 8 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $11 | $2.99 | +267.89% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $6.76 | +417.75% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $29.46 | +86.69% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $28.40 | +30.28% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $17.37 | +49.68% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $20.10 | -0.50% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.13 | +32.74% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $22.02 | +81.65% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $89.65 | -16.34% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $13.14 | +37.04% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $26.95 | -55.47% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.41 | +264.96% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.58 | +481.40% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $9.08 | -66.96% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $1.45 | +4,727.59% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $16.16 | +234.16% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $59.58 | +51.06% | 5 | Mar 14, 2022 |
Intellia Therapeutics
Oct 27, 2025
Maintains: Buy
Price Target: $36 → $30
Current: $8.48
Upside: +253.77%
United Therapeutics
Sep 2, 2025
Maintains: Neutral
Price Target: $314 → $463
Current: $471.92
Upside: -1.89%
Mineralys Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $38 → $43
Current: $44.26
Upside: -2.85%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $35.44
Upside: -12.53%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $11.89
Upside: +68.21%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $66.90
Upside: -14.80%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Sector Perform
Price Target: $442 → $438
Current: $434.02
Upside: +0.92%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $460.54
Upside: -2.29%
Agios Pharmaceuticals
Jul 28, 2025
Maintains: Sector Outperform
Price Target: $71 → $65
Current: $45.13
Upside: +44.03%
Rocket Pharmaceuticals
Jul 25, 2025
Downgrades: Neutral
Price Target: $9 → $4
Current: $3.04
Upside: +31.58%
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $2.99
Upside: +267.89%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $6.76
Upside: +417.75%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $29.46
Upside: +86.69%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $28.40
Upside: +30.28%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $17.37
Upside: +49.68%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $20.10
Upside: -0.50%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.13
Upside: +32.74%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $22.02
Upside: +81.65%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $89.65
Upside: -16.34%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $13.14
Upside: +37.04%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $26.95
Upside: -55.47%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.41
Upside: +264.96%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.58
Upside: +481.40%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $9.08
Upside: -66.96%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $1.45
Upside: +4,727.59%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $16.16
Upside: +234.16%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $59.58
Upside: +51.06%